| 楼海舟,潘宏铭,金伟,郑宇,楼芳,方勇.艾迪注射液联合冷循环射频消融术治疗肝癌的研究[J].中国中西医结合杂志,2007,(5):393-395 |
| 艾迪注射液联合冷循环射频消融术治疗肝癌的研究 |
| Clinical Study on Treatment of Primary Liver Cancer by Aidi Injection Combined with Cool-tip Radiofrequency Ablation |
| 免费下载全文 查看/发表评论 下载PDF阅读器 |
| |
| DOI： |
| 中文关键词: 肝癌 射频消融术 艾迪注射液 |
| 英文关键词:liver cancer radiofrequency ablation Aidi Injection |
| 基金项目: |
|
| 摘要点击次数: 1343 |
| 全文下载次数: 2 |
| 中文摘要: |
| 目的观察艾迪注射液联合经皮冷循环射频消融术治疗肝癌的疗效及不良反应,及其对机体免疫功能影响。方法89例中晚期原发性肝癌患者分为联合治疗组和单纯射频组。单纯射频组予冷循环射频消融术,联合治疗组在射频术后给予艾迪注射液50mL静脉滴注每天1次,连用20天。结果联合治疗组治疗前后丙氨酸转氨酶(ALT)及血清白蛋白(ALB)水平无明显变化,CD4细胞亚群和CD4/CD8比例治疗后较治疗前明显增高(P<0·01);而单纯射频组治疗后ALT升高(P<0·05),ALB显著下降(P<0·01),CD4细胞亚群和CD4/CD8比例无明显变化。在>3cm的肿瘤中1年内随访联合治疗组的复发率为20·0%(3/15个),小于单纯射频组的复发率55·0%(11/20个,P<0·05)。结论射频消融联合艾迪注射液治疗原发性肝癌可减轻射频消融对肝功能损害,提高机体免疫力,降低复发率。 |
| 英文摘要: |
| Objective To investigate the therapeutic efficacy and adverse reactions of Aidi Injection(AI) combined with percutaneous cool-tip radiofrequency ablation(CRFA) in treatment of primary liver cancer and to explore its effect on immune function.Methods Eighty-nine patients with primary liver cancer at middle-late stage were assigned to the control group with CRFA alone and the treatment group treated with CRFA and intravenous dripping of AI 50 mL once every day for succesive 20 days.Results Compared with those before treatment,the alanine aminotransferase(ALT) and albumin(ALB) levels showed no marked change,and CD4 subgroup of T lymphocyte and CD4/CD8 ratio elevated in the treatment group(P<0.01),while the ALT level elevated(P<0.05),ALB level decreased(P<0.01),CD4 and CD4/CD8 ratio showed no change in the control group.The relapse rate was 20.0%(3/15) in patients with tumor more than 3 cm in diameter of the treatment group,which was obvious lower than that in the control group(55.0%,11/20,P<0.05).Conclusion AI treatment could relieve the impairment of CRFA on hepatic function,improve immune function and reduce relapse rate in patients with primary liver cancer. |
| 关闭 |
|
|
|
扫描微信二维码，获取更多信息